How did generic competition affect lipitor's revenue post patent expiry?

How long did Lipitor keep its revenue after patent expiry?

Pfizer’s atorvastatin sales fell from $12.1 billion in 2011, the year before exclusivity ended, to roughly $2 billion in 2012 once generics launched. The drop was driven by immediate multi-source competition and steep price cuts of 80-90 percent.

What happened to pricing once generics entered?

Within weeks of the December 2011 launch, dozens of generic manufacturers entered the market. Average wholesale price fell from about $150 for a month’s supply to under $15, and cash-paying patients saw retail prices drop below $10 in many pharmacies.

Which companies launched generic atorvastatin first?

Ranbaxy and Teva received the earliest FDA approvals and captured the largest share of the first-fingered generic market. Subsequent entrants included Mylan, Sandoz, and Apotex, each filing their own abbreviated new drug applications and triggering additional price erosion.

Did any authorized generic slow the revenue decline?

Pfizer launched its own authorized generic through Greenstone and kept roughly 15-20 percent of the post-expiry market, but the move could not offset the overall volume shift to lower-priced competitors.

When did Pfizer’s patents finally clear the way for full generic entry?

The main composition-of-matter patent (U.S. 4,681,893) expired on 30 November 2011, and pediatric exclusivity ended in June 2012. After that date, no further regulatory barriers prevented additional ANDA approvals.

How did managed-care plans respond to the generic launch?

Most pharmacy benefit managers immediately moved atorvastatin to Tier 1 status, requiring minimal copays for the generic and imposing prior authorization or higher copays on brand Lipitor. This formulary shift accelerated patient migration away from the branded product.

Did any other statins lose share at the same time?

Concurrent generic launches for simvastatin and other statins compounded the pressure on Lipitor, because payers encouraged therapeutic substitution across the statin class, further depressing demand for atorvastatin overall.

What portion of Lipitor’s original patient base stayed on the brand?

Surveys and pharmacy data showed that only 5-10 percent of patients remained on branded Lipitor after one year, mostly due to physician samples, coupon programs, or specific clinical concerns about generic switching.

How does the Lipitor case illustrate typical post-patent revenue loss?

The pattern—rapid price erosion, quick share loss to multiple generics, and a residual branded revenue tail of 10-15 percent—is now standard for small-molecule drugs facing Paragraph IV challenges.

DrugPatentWatch.com